COMMUNIQUÉS West-GlobeNewswire

Informations relatives au nombre total de droits de vote et d’actions composant le capital
20/01/2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 20 janvier 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
CARBIOS : Bilan semestriel du contrat de liquidité confié à Natixis ODDO BHF et annonce de sa suspension
20/01/2026
Titre concerné : CARBIOS (code ISIN FR0011648716) Marché concerné : Euronext Growth Paris Clermont-Ferrand (France), le 20 janvier 2026 (18h00 CET). CARBIOS présente le bilan semestriel du contrat de liquidité conclu [...]
CARBIOS : half-year report on the liquidity contract entrusted to Natixis ODDO BHF and notice of suspension
20/01/2026
PRESS RELEASE Shares concerned: Carbios (ISIN code: FR0011648716) Market concerned: Euronext Growth Paris Clermont-Ferrand, France, January 20, 2026 (6:00 pm CET). CARBIOS today presents the half-year report on the [...]
Bilan semestriel du contrat de liquidité avec Invest Securities
20/01/2026
Bilan semestriel du contrat de liquidité avec Invest Securities Nantes, le 20 janvier 2026, 18 heures – Au titre du contrat de liquidité confié par OSE Immunotherapeutics à Invest Securities, les moyens suivants [...]
Half-Year Report on Liquidity Contract with Invest Securities
20/01/2026
Half-Year Report on Liquidity Contract with Invest Securities NANTES, France - January 20, 2026, 6:00pm CET – Under the liquidity contract entrusted by OSE Immunotherapeutics to Invest Securities, the following [...]
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
20/01/2026
VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
20/01/2026
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second [...]
Genvor, Inc. to Present at the 3rd Annual DealFlow Discovery Conference
20/01/2026
Woodland, CA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a biotechnology company pioneering AI-accelerated peptide technology for sustainable agriculture, today announced that it will participate in the [...]
Avacta Announces Year-end Trading Update
20/01/2026
LONDON and PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, has [...]
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
20/01/2026
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injury Participants to include people with Long COVID who [...]
Kraig Biocraft Laboratories Rings in the New Year with the Most Ambitious Genetic Engineering Program in its History
20/01/2026
ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced that it is [...]
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
20/01/2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its [...]
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
20/01/2026
The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering [...]
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
20/01/2026
FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of [...]
Glass House Brands Announces Accelerated 2026 Expansion Strategy
20/01/2026
The Company is accelerating expansion efforts with plans to commence production in two additional greenhouses and planting its first production intended for sale in markets outside of California. Accelerated expansion [...]
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
20/01/2026
- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE Registrational [...]
Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting
20/01/2026
-- Met Primary Endpoint with 30mg Dose of RE104 with 23.0-Point Total Score Reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) on Day 7 (p=0.0094) -- -- Demonstrated Rapid and Durable Efficacy Starting as [...]
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
20/01/2026
-- Designation highlights significant unmet medical need AUSTIN, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in- [...]
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
20/01/2026
- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in [...]

Pages